CN102755628A - Antifungal pharmaceutical composition - Google Patents
Antifungal pharmaceutical composition Download PDFInfo
- Publication number
- CN102755628A CN102755628A CN201210245954XA CN201210245954A CN102755628A CN 102755628 A CN102755628 A CN 102755628A CN 201210245954X A CN201210245954X A CN 201210245954XA CN 201210245954 A CN201210245954 A CN 201210245954A CN 102755628 A CN102755628 A CN 102755628A
- Authority
- CN
- China
- Prior art keywords
- posaconazole
- antifungal
- quinomycin
- following
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antifungal pharmaceutical composition which is composed of A and B, wherein A is selected from at least one of quinoxaline antibiotics, and analogs, derivatives, prodrugs, metabolites and pharmaceutical active salts thereof; and B is selected from at least one of triazole compounds, and analogs, derivatives, prodrugs, metabolites and pharmaceutical active salts thereof. The in-vitro antimicrobial test proves that the combination of posaconazole and echinomycin has strong synergic activity. When the amounts of the posaconazole and echinomycin are respectively reduced by 32-64 times, the posaconazole and echinomycin can still ensure that the test fungi can be 100% cleared in an in-vitro test. The antifungal pharmaceutical composition can provide combined treatment, and is effective for refractory and invasive fungal infections, thereby lowering the amounts of posaconazole, relieving the economic burden of the patient, reducing the toxic reaction of posaconazole and effectively reducing the development of drug tolerance of fungi.
Description
Technical field
The present invention relates to a kind of antifungal medicament compositions.
Background technology
Fungal infection, the especially sickness rate of hypoimmunity patient opportunistic fungal infection constantly rise treatment of fungal infections are faced with formidable challenges.Though there are some fungi-medicines to come out one after another, treatment has brought new favourable turn to fungal infection, and the simultaneously relevant drug-fast report of Drug therapy also increases gradually.Therefore need the new antifungal therapy method of development.
Posaconazole generally is used for intractable and invasive infections with fungi or other medicines drug resistance cause fungal infection.This kind infection generally occurs on one's body the patient of immunity infringement, for example organ transplantation or carry out the patient of chemotherapy.Compare with itraconazole with the control drug fluconazol of anti-fungal infection, posaconazole more can effectively prevent the aggressive aspergillin infection and can reduce the relevant mortality rate of invasive infections with fungi.But posaconazole costs an arm and a leg, and often follows some serious adverse reactions such as hyperbilirubinemia in the therapeutic process, and liver enzyme raises, symptoms such as hepatocellular damage and nausea and vomiting.
Summary of the invention
The purpose of this invention is to provide a kind of antifungal medicine composition with synergistic function.
Antifungal medicine composition provided by the present invention is made up of A and B; Wherein, Said A is selected from following at least a: quinoxaline antibiotic and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt, said B is selected from following at least a: triazole class compounds and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In some embodiments, said A is selected from following any one material: Quinomycin A. and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In some embodiments, said B is selected from following any one material: posaconazole and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In the preferred embodiment, said A is a Quinomycin A., and said B is a posaconazole, and both mass ratioes are (12.5-1600): 1, and preferred mass is than being (200-1600): 1.
Antibiotic of quinoxaline described in the present invention and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt can obtain through microbial fermentation, chemical improvement, chemosynthesis or commercial sources.
Triazole class compounds described in the present invention and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt can obtain through chemosynthesis or commercial sources.
Another object of the present invention provides the application of above-mentioned antifungal medicine composition.
To be it be used for treating the application of the medicine of fungal infection in preparation in application provided by the present invention.
In some embodiments, the fungus that is infected can be selected from but be not limited to by aspergillosis, Fusarium spp., Candida albicans (being saccharomyces albicans).
The present invention also protects a kind of medicine that is used to treat fungal infection.
The medicine that the present invention protected, its active component are antifungal medicine composition of the present invention.
But the method for said medicine administered through oral, external, injection, infiltration, absorption, physics or chemistry mediation imports body such as muscle, Intradermal, subcutaneous, vein or mucosal tissue; Or by other material mixing or parcel back importing body.
When needing, in said medicine, can also add one or more pharmaceutically acceptable carriers.Said carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier and the lubricant etc. that pharmaceutical field is conventional.
The said medicine that is used to treat fungal infection can be processed various ways such as injection, tablet, powder, granule, capsule, unguentum, cream.The medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.
The in-vitro antibacterial evidence with posaconazole and Quinomycin A. Combined application, shows very strong synergistic activity.Make both sides' dosage all reduce 32-64 doubly, still can guarantee to be tried fungus in the experiment in vitro and removed by 100%.Such compositions will provide therapeutic alliance, and will be intractable for having, and invasive fungal infection is effective.And can therefore reduce the dosage of posaconazole, alleviate patient's financial burden, alleviate the toxic reaction of posaconazole, effectively reduce the chemical sproof development of fungus.
Description of drawings
Fig. 1 is the collaborative antifungal activity result (composition of medicine MIC value during 100% inhibition conk) of posaconazole and Quinomycin A.
The specific embodiment
The present invention will be described through specific embodiment below, but the present invention is not limited thereto.
Experimental technique described in the following embodiment like no specified otherwise, is conventional method; Said reagent and biomaterial like no specified otherwise, all can obtain from commercial sources.
Used Candida albicans (Candida albicans SC5314/ATCC MYA-2876) is available from the biological article collecting center (American Type Culture Collection) of Unite States Standard among the following embodiment.
The interactive antifungal activity test of embodiment 1, Quinomycin A. and posaconazole
Using chessboard method tests interactive antifungal (the Candida albicans SC5314) activity of Quinomycin A. and posaconazole.Concrete grammar is:
Candida albicans SC5314 in the RPMI1640 culture medium, 35 ℃, humidity 80%, 5%CO
2Condition under hatch.Quinomycin A. and posaconazole are dissolved in respectively among the DMSO, to concentration be 1mg/mL, stored for future use in refrigerator.In order to measure minimal inhibitory concentration (MIC), adopt doubling dilution during sample test.Specifically with reference to the M-27A of standardization committee of American National clinical laboratory (NCCLS) scheme, i.e. " yeast liquid media dilution method antifungal drug STT scheme ".Adopt 2 times of dilution methods to prepare the medicinal liquid of a series of diluted concentrations with fluid medium (RPMI1640), then with Candida albicans SC5314 cell (78 μ l ,～1 * 10
4Individual) be inoculated in 96 orifice plates, the back adds 2 μ l drug solutions.First medicine posaconazole is vertically arranged by diluted concentration on 96 orifice plates, and second medicine Quinomycin A. laterally arranged by diluted concentration.Hatch test OD value after 18 hours for 35 ℃.Compare to confirm the MIC value through OD value with blank.The MIC value defined is the lowest drug concentration that ability 100% suppresses conk here.
For confirm to work in coordination with between two medicine A and the B, addition or antagonism, we judge through inhibition concentration coefficient FICI.FICI=(A/MICA in the MIC drug regimen is independent)+(B/MICB in the MIC drug regimen is independent) is if FICI value＜0.50 then shows to have interactive activity; If the FICI value is between 0.5-4.0; Then for showing active addition, if FICI value＞4.0 then show to have antagonism between the two.
Table 1. is worked in coordination with the antifungal activity test result
The result shows that posaconazole concentration is 0.002ug/ml, and Quinomycin A. concentration is 0.025ug/ml; Posaconazole concentration is 0.001ug/ml, and Quinomycin A. concentration is 0.05ug/ml; Posaconazole concentration is 0.0005ug/ml, and Quinomycin A. concentration is 0.1ug/ml; Posaconazole concentration is 0.00025ug/ml, and Quinomycin A. concentration is 0.1ug/ml; Posaconazole concentration is 0.000125ug/ml, and all there was collaborative antifungic action in two chemical compounds when Quinomycin A. concentration was 0.2ug/ml.Wherein posaconazole concentration is 0.00025ug/ml, and when Quinomycin A. concentration was 0.1ug/ml, collaborative antifungal activity was the strongest.
Claims (8)
1. an antifungal medicine composition is made up of A and B; Wherein, said A is selected from following at least a: quinoxaline antibiotic and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt; Said B is selected from following at least a: triazole class compounds and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
2. antifungal medicine composition according to claim 1 is characterized in that: said A is selected from following any one material: Quinomycin A. and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
3. antifungal medicine composition according to claim 1 and 2 is characterized in that: said B is selected from following any one material: posaconazole and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
4. according to each described antifungal medicine composition among the claim 1-3, it is characterized in that: said A is a Quinomycin A., and said B is a posaconazole, and the mass ratio of said Quinomycin A. and posaconazole is (12.5-1600): 1.
5. each described antifungal medicine composition is used for treating the application of the medicine of fungal infection among the claim 1-4 in preparation.
6. application according to claim 5 is characterized in that: said fungal infection is caused by following at least a fungus: aspergillosis, Fusarium spp. and Candida albicans.
7. medicine that is used to treat fungal infection, its active component is each described antifungal medicine composition among the claim 1-4.
8. medicine according to claim 7 is characterized in that: said fungal infection is caused by following at least a fungus: aspergillosis, Fusarium spp. and Candida albicans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210245954 CN102755628B (en) | 2012-07-16 | 2012-07-16 | Antifungal pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210245954 CN102755628B (en) | 2012-07-16 | 2012-07-16 | Antifungal pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102755628A true CN102755628A (en) | 2012-10-31 |
| CN102755628B CN102755628B (en) | 2013-10-23 |
Family
ID=47050435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210245954 Expired - Fee Related CN102755628B (en) | 2012-07-16 | 2012-07-16 | Antifungal pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102755628B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688306A (en) * | 2002-09-23 | 2005-10-26 | 先灵公司 | Use of posaconazole for the treatment of fungal infections |
| CN1988887A (en) * | 2004-05-28 | 2007-06-27 | 先灵公司 | Injectable pharmaceutical suspension comprising posaconazole |
| CN102391968A (en) * | 2011-11-17 | 2012-03-28 | 中国科学院微生物研究所 | Streptomyces and its application in echinomycin production |
-
2012
- 2012-07-16 CN CN 201210245954 patent/CN102755628B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688306A (en) * | 2002-09-23 | 2005-10-26 | 先灵公司 | Use of posaconazole for the treatment of fungal infections |
| CN1988887A (en) * | 2004-05-28 | 2007-06-27 | 先灵公司 | Injectable pharmaceutical suspension comprising posaconazole |
| CN102391968A (en) * | 2011-11-17 | 2012-03-28 | 中国科学院微生物研究所 | Streptomyces and its application in echinomycin production |
Non-Patent Citations (2)
| Title |
|---|
| 陈念等: "喹喔啉类抗肿瘤抗生素研究进展", 《实用医学杂志》, vol. 22, no. 21, 30 November 2006 (2006-11-30), pages 2569 - 2570 * |
| 陈敏等: "泊沙康唑治疗侵袭性真菌病研究进展", 《中国实用内科杂志》, vol. 32, no. 2, 29 February 2012 (2012-02-29), pages 154 - 157 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102755628B (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536613B (en) | A kind of antifungal pharmaceutical composition | |
| Chatelon et al. | Choosing the right antifungal agent in ICU patients | |
| CN102008481A (en) | Eprosartan-containing compound preparation for treating hypertension | |
| CN102008711B (en) | Compound preparation containing enalapril for treating hypertension | |
| CN101505797A (en) | Pharmaceutical compositions for the treatment of fungal infections | |
| US11554109B2 (en) | Pemafibrate dosing regimens | |
| Soysal | Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole | |
| KR101572529B1 (en) | Tetraarsenic oxide combination therapy for cancer treatment | |
| CN101407520A (en) | Novel medical uses of aporphine alkaloid and derivative thereof | |
| Said et al. | Sirolimus‐itraconazole interaction in a hematopoietic stem cell transplant recipient | |
| JP2020529999A (en) | Antifungal agent showing enhanced activity at acidic pH | |
| CN102755628B (en) | Antifungal pharmaceutical composition | |
| KR101632042B1 (en) | Pharmaceutical compositions containing fk506 derivatives and their use for the treatment of fungal infection by cryptococcus sp. and candida sp. fungi | |
| CN108042532A (en) | A kind of antimycotic pharmaceutical composition | |
| CN116808055A (en) | Method for resisting novel cryptococcus by combining sclareolide and amphotericin B | |
| Beggs | Combined activity of ketoconazole and sulphamethoxazole against Candida albicans | |
| Preston et al. | Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia | |
| CN102526081A (en) | Medicinal composition capable of inhibiting proliferation of tumor cells | |
| RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) | |
| EP3028693A1 (en) | Stable solid immunosuppressor composition | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN102872059A (en) | Application of Gypensapogenin B to preparing drugs for resisting human funguses | |
| CN111603470A (en) | Application of itraconazole isomer in preparation of drugs for treating squamous non-small cell lung cancer | |
| CN102861027B (en) | Application of Gypensapogenin A in medicine for preventing human fungi | |
| Deck et al. | Pharmacological advances in the treatment of invasive candidiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 Termination date: 20200716 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |